Citadel Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Citadel Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-115,925	Closed	-$32K	–	15978
2022 Q3	$32K	Buy	+115,925	New	+$45.9K	﹤0.01%	11885
2022 Q1	–	Sell	-18,600	Closed	-$20.4K	–	15099
2021 Q4	$43K	Buy	+18,600	New	+$62.9K	﹤0.01%	13334
2021 Q3	–	Sell	-14,250	Closed	-$62.7K	–	15092
2021 Q2	$63K	Buy	+14,250	New	+$72.5K	﹤0.01%	13227
2021 Q1	–	Sell	-32,430	Closed	-$248K	–	13918
2020 Q4	$248K	Buy	+32,430	New	+$217K	﹤0.01%	9412

Citadel Advisors's LOGC Position: Q4 2022 in Review

Citadel Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 115,925 shares — an estimated $32K sold.

Citadel Advisors first reported a position in LOGC in Q4 2020 and held it in 4 quarters. The position peaked at $248K in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Citadel Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 115,925 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $32K.
Citadel Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Citadel Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $248K in Q4 2020.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.